Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE-PMR: Rituximab for Glucocorticoid Sparing in Polymyalgia Rheumatica
2018-002641-11Phase 2Completed
- Sponsor
- Sint Maartenskliniek
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rituximab in polymyalgia rheumatica (PMR), sponsored by Sint Maartenskliniek. Primary endpoint: Proportion of PMR patients in glucocorticoid-free remission at 20 weeks. Started Jul 2018; status: completed.
02
Drugs
rituximab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2018-002641-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002641-11.